Imipenem

**Imipenem** is a small-molecule antibacterial drug in the carbapenem class, not a protein or classical "target" but the active agent in several antibiotic formulations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in bacterial cell death. It is frequently administered in combination with cilastatin (a dehydropeptidase I inhibitor that prevents its renal breakdown) and, recently, with relebactam (a β-lactamase inhibitor), for enhanced activity against antibiotic-resistant Gram-negative and Gram-positive bacteria. Imipenem is considered a "last-resort" broad-spectrum antibiotic, reserved for severe or resistant infections[1][6][7]. Imipenem is not a biological target but an antibacterial agent; the therapeutic target for drugs like imipenem would be the bacterial penicillin-binding proteins. Imipenem is **not itself a therapeutic target** (such as an enzyme, receptor, transporter, etc.), but rather a **drug (small molecule)** with antibacterial action. Its biological mechanism targets bacterial PBPs; thus, answering under your criteria, "is_target" should be "false" and "is_incorrect" should be "true" (since the prompt asks about the drug as a target, which is a mismatch)[1][6][7].

Other names

N-formimidoyl thienamycinN-formimidoylthienamycinImipenem anhydrousImipenemumImipenem hydrateImipenem monohydrate(5R,6S)-3-((2-(Formimidoylamino)ethyl)thio)-6-((R)-1-hydroxyethyl)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid

It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in bacterial cell death.